Last reviewed · How we verify
Exosomes overexpressing CD24 — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
Exosomes overexpressing CD24 (Exosomes overexpressing CD24) — Eli Sprecher, MD.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Exosomes overexpressing CD24 TARGET | Exosomes overexpressing CD24 | Eli Sprecher, MD | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Exosomes overexpressing CD24 CI watch — RSS
- Exosomes overexpressing CD24 CI watch — Atom
- Exosomes overexpressing CD24 CI watch — JSON
- Exosomes overexpressing CD24 alone — RSS
Cite this brief
Drug Landscape (2026). Exosomes overexpressing CD24 — Competitive Intelligence Brief. https://druglandscape.com/ci/exosomes-overexpressing-cd24. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab